Robotics Bottleneck Research机器人瓶颈研究

Main主页 / companies / public / robotis

company

RobotisRobotis 108490

Country国家 Korea韩国

Systems系统 Muscle肌肉

Bottlenecks瓶颈 P14 Actuators, reducers, encoders执行器、减速器与编码器

Market cap市值 Live, via TradingView.实时数据,来自 TradingView。

Dynamixel smart actuators and precision drives (98% of H1 2026 revenue) for the global robotics research and prototyping market. Q2 2026 operating profit +722.9% YoY on accelerating China exports the company attributes explicitly to humanoid demand.

Dynamixel 智能执行器与精密传动装置——占 2026 年上半年收入的 98%——面向全球机器人研究与原型开发市场。2026 年二季度营业利润同比 +722.9%,公司将加速的对华出口明确归因于人形机器人需求。

What it doesDynamixel smart actuators and precision drives (98% of H1 2026 revenue) for the global robotics research and prototyping market. Q2 2026 operating profit +722.9% YoY on accelerating China exports the company attributes explicitly to humanoid demand.

在干什么Dynamixel 智能执行器与精密传动装置——占 2026 年上半年收入的 98%——面向全球机器人研究与原型开发市场。2026 年二季度营业利润同比 +722.9%,公司将加速的对华出口明确归因于人形机器人需求。

Name sheetRobotis

Why it mattersDynamixel is the de facto standard actuator across the global robotics research and prototyping community, giving Robotis an unusually wide installed base of engineers who first learn robotics on its hardware. A twenty-year, near-single-product focus on smart actuators (97.99% of H1 2026 consolidated revenue) makes it the closest Korean listed comparable to Harmonic Drive Systems' actuation-only purity, at a small fraction of the scale, and one of the only Korean P14 names whose own management explicitly names humanoid demand as a growth driver.

为何重要Dynamixel 是全球机器人研究与原型开发领域事实上的标准执行器,使 Robotis 拥有异常广泛的工程师装机基础,许多人正是从其硬件入门机器人学习。二十年来近乎单一产品聚焦于智能执行器——占 2026 年上半年合并收入的 97.99%——使其成为韩国上市公司中在“纯执行器”定位上最接近哈默纳科的一家,只是规模小得多;也是少数管理层明确将人形机器人需求列为增长驱动因素的韩国 P14 标的之一。

Caveat

For Q2 2026 (three months to June 2026), disclosed via DART and reported in Korean financial press on 2026-08-17, consolidated revenue was KRW 15.37bn, up 95.1% year over year, and operating profit was KRW 1.98bn, up 722.9%, an operating margin that moved from roughly low single digits a year earlier to roughly 12.9%. Actuator sales were KRW 26.67bn for H1 2026, representing 97.99% of consolidated H1 revenue, effectively a single-product company.

Exports to China roughly tripled quarter over quarter in Q2 2026, and the company attributes the growth explicitly to humanoid-robot demand, unlike Nabtesco and Harmonic Drive Systems in Japan, both of which have declined to name humanoids as a driver in their own disclosures. Robotis states it supplies actuators to more than 70 customers globally, with a company-disclosed regional revenue split of roughly 40% domestic, 32% US and 12% China, a mix, not a named-customer breakdown.

In August 2026 Robotis showed its own humanoid platform, 'AI Sapiens,' at the World Robot Conference in Beijing to promote its forthcoming Dynamixel-Q actuator line, and is investing KRW 60bn to build a dedicated Dynamixel-Q factory in Uzbekistan aimed at China market entry, a capacity commitment, not yet capacity delivered or revenue. Robotis remains small in absolute terms: H1 2026 total revenue of roughly KRW 27.2bn implies a market capitalisation (KRW 3.84tn as of 2026-08-21) of roughly 70x annualised revenue, a rich multiple for a company whose customer base is still described qualitatively (research labs, prototype developers, an unnamed set of 70-plus clients) rather than through named industrial or humanoid-OEM supply contracts.

No single named humanoid customer or unit-volume figure has been disclosed.

风险提示

2026 年二季度(截至 2026 年 6 月的三个月),经 DART 披露并于 2026-08-17 由韩国财经媒体报道:合并收入 153.7 亿韩元,同比 +95.1%;营业利润 19.8 亿韩元,同比 +722.9%——营业利润率从上年同期的低个位数升至约 12.9%。2026 年上半年执行器销售额为 266.7 亿韩元,占合并收入的 97.99%——实质上是单一产品公司。

2026 年二季度对华出口环比增长约三倍,公司明确将这一增长归因于人形机器人需求,这与日本的纳博特斯克和哈默纳科不同——后两者在自身披露中均未将人形机器人列为驱动因素。Robotis 表示其执行器产品面向全球 70 余家客户,公司披露的地区收入结构约为:国内 40%、美国 32%、中国 12%——这是一个结构比例,而非具名客户明细。

2026 年 8 月,Robotis 在北京世界机器人大会上展示了自研人形机器人平台 “AI Sapiens”,以推广即将推出的 Dynamixel-Q 执行器产品线,并正投资 600 亿韩元在乌兹别克斯坦建设专用 Dynamixel-Q 工厂,目标是打入中国市场——这是产能承诺,尚非已交付的产能或收入。Robotis 绝对规模仍然很小:2026 年上半年总收入约 272 亿韩元,对应市值(截至 2026-08-21 为 3.84 万亿韩元)约为年化收入的 70 倍——对于一家客户基础仍以定性描述(研究实验室、原型开发者、未具名的 70 余家客户)而非具名工业或人形 OEM 供货合同来呈现的公司而言,这是一个偏高的倍数。

公司未披露任何具名人形客户或出货量数字。

ProductDynamixel smart actuator modules, the cycloid Dynamixel Drive line, and service-robot platforms

Value accrualContent per actuator unit, an unusually wide installed base among robotics developers, and emerging qualification with humanoid programmes entering the China market

Key riskH1 2026 revenue ~KRW 27.2bn against a market cap of ~KRW 3.84tn (P/S ~70x annualised); 97.99% single-product (actuator) revenue concentration; no named humanoid-OEM customer or unit volume disclosed despite explicit humanoid-demand attribution in company commentary.

Key risk2026 年上半年收入约 272 亿韩元,对应市值约 3.84 万亿韩元(年化市销率约 70 倍);97.99% 的收入集中于单一产品(执行器);尽管公司在评论中明确将增长归因于人形机器人需求,但未披露任何具名人形 OEM 客户或出货量。

Bottlenecks瓶颈 P14 Actuators, reducers, encoders执行器、减速器与编码器

Class
public
Country
KR
HQ
Seoul, South Korea
Layer
Actuation / Smart actuators
Systems
muscle
Caveat stance
watch
Ticker
108490
Exchange
KOSDAQ
Purity
High (97.99% of H1 2026 revenue from actuators; near-single-product company)
Valuation tier
3
Last verified
2026-08-26
Sources
S-PUB-034 · S-PUB-035
Translated fields
what_it_does_en · why_it_matters_en · caveat_en · key_risk_en
Chain position
upstream
COMPANY RESEARCH公司研究 Commercial evidence商业证据 Expand +展开 + Collapse −收起 −
Commercial evidence shows how far a company has moved from a product claim to repeatable customer value. We look for a defined customer task, paid deployment, operating results, the human help required, and economics that can support repeat use. Missing information stays unassessed; it does not count as evidence against the company.商业证据用于判断一家公司从产品宣称走到了可重复客户价值的哪一步。我们关注明确的客户任务、付费部署、运行结果、所需人工协助,以及能否支持重复采用的经济性。缺失信息保持未评估,不会被当作对公司的负面证据。 Each item below applies only to the cited document and period. It should be read with its evidence class, review date, and stated limits.以下每项内容仅适用于所引文件与期间,阅读时应同时考虑证据类别、核查日期与已说明的局限。
Customer and task
客户与任务
Not yet assessed in this structured record.本结构化记录尚未评估。
Deployment and payment
部署与付款
Not yet assessed in this structured record.本结构化记录尚未评估。
Task results and human assistance
任务结果与人工协助
Not yet assessed in this structured record.本结构化记录尚未评估。
Cost and repeat purchases
成本与复购
Not yet assessed in this structured record.本结构化记录尚未评估。
What the evidence cannot establish
证据的局限
Not yet assessed in this structured record.本结构化记录尚未评估。
How to evaluate commercial evidence如何评估商业证据